stockrow
Saturday 7 November 2026
Export BNTC’s income statement to Excel — free account
Benitec Biopharma Limited
BNTC Healthcare Biotechnology
Benitec Biopharma Limited’s revenue for fiscal 2023 (year ended June 2023) was $75,000.00, up 2.74% from fiscal 2022.
- EPS
- −11.3%
- Free cash flow
- +38.9%
- Total debt
- −46.3%
Quarter to June 2026, against a year earlier
9.50
0.86
+9.95%
Follow BNTC
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
33.70 | 56.47 | 67.49 | 46.72 | |
Current Ratio |
34.00 | 56.82 | 67.69 | 46.95 | |
Net Debt/EBITDA |
12.48 | 13.60 | 14.10 | 9.62 | |
Debt/Assets |
0.15% | 0.21% | 0.27% | 0.42% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.39 | 0.37 | 0.32 | 0.37 | |
Capex/Depreciation |
(4.65) | (1.07) | (0.79) | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.11) | (0.09) | (0.08) | (0.08) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.11) | (0.09) | (0.08) | (0.08) | |
Cash per Share |
3.87 | 3.74 | 4.11 | 2.28 | |
Shareholders Equity per Share |
3.80 | 3.71 | 4.08 | 2.25 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.80 | 3.71 | 4.08 | 2.25 | |
Free Cash Flow |
(5.02) | (4.47) | (3.79) | (3.35) | |
Working Capital |
176.34 | 182.74 | 186.79 | 93.05 | |
Capital Expenditures |
(0.08) | (0.01) | (0.01) | — | |
Net Current Asset Value |
176.08 | 182.35 | 186.28 | 92.65 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | — | |
| Other line items | |||||
Average Receivables |
0.02 | 0.00 | 0.07 | 0.01 | |
Average Payables |
2.66 | 4.25 | 2.13 | 2.50 | |
Average Assets |
141.11 | 146.10 | 134.87 | 82.40 | |
Average Common Equity |
137.15 | 140.45 | 131.65 | 78.89 |
Columns are period end dates · fundamentals updated 26 Oct 2026